Biography
Hubert Chen is SVP of Clinical Development at Krystal Biotech, where he leads a growing portfolio of clinical-stage programs utilizing Krystal’s HSV-1–based platform to enable the development of redosable gene therapies for rare, life-threatening conditions, including dystrophic epidermolysis bullosa and cystic fibrosis. Hubert is a physician-scientist with over a decade of industry experience spanning all phases of drug development from first-in-human to launch. Previously, Hubert was Principal Medical Director at Genentech where he led the FDA approval for omalizumab in chronic spontaneous urticaria and was responsible for the advancement of multiple early-stage programs in the respiratory/immunology pipeline. Hubert began his career as an assistant professor in the pulmonary division at UCSF and has published over 40 peer-reviewed articles in the field of respiratory medicine. He is board-certified in pulmonary and critical care medicine. He received his MD from Stanford, his MPH from Harvard, and completed his fellowship at UCSF.

Emerging Therapeutics Showcase:
Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas.

Redosable Gene Therapies Utilizing a HSV-1-based Platform
Krystal Biotech has created a proprietary HSV-1–based platform, enabling development of redosable gene therapies.